|
|
| ÂÒá¡éËÇÑ´ | 5 |  | 4.17 |
| ÃÒ¤Ò ÂÒʵÃÕàÅ´Ô¹èÒ | 3 | | 2.50 |
| ¢Ñ鹵͹¡ÒÃÊè§ÍÍ¡ à¤Ã×èͧÊÓÍÒ§ | 3 | | 2.50 |
| ÂÒÅÐÅÒÂÅÔèÁàÅ×Í´ | 3 | | 2.50 |
| ¤ÙèÁ×Í·ÓÇѵÃàªéÒ-àÂç¹ ÊǹâÁ¡¢¾ÅÒÃÒÁ | 2 | | 1.67 |
| à»Ô´ÃéÒ¹¢ÒÂÂÒÊÒÁÑ»ÃШíÒºéÒ¹ | 2 | | 1.67 |
| ͧ¤ì¡ÒÃÍÒËÒÃáÅÐÂÒ | 2 | | 1.67 |
| 䫺ٷÃÒÁÕ¹ | 2 | | 1.67 |
| ÊÃþ¤Ø³âËÂè§àËÔ§ | 2 | | 1.67 |
| ·ÕèÍÂÙèâç§Ò¹¼ÅÔµÂÒ âËÂè§àËÔ§ | 2 | | 1.67 |
| ¡®ËÁÒ Í | 2 | | 1.67 |
| ÂÒ | 2 | | 1.67 |
| ·ÕèÍÂÙèâç§Ò¹¼ÅÔµÂÒ + âËÂè§àËÔ§ | 2 | | 1.67 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ (©ºÑº·Õè 9) ¾.È. 2536 | 1 | | 0.83 |
| ÁËѹµÀÑÂä´ÍÍ¡«Ô¹ | 1 | | 0.83 |
| botox cosmetic | 1 | | 0.83 |
| ÃéÒ¹¢ÒÂÂÒÊѵÇì | 1 | | 0.83 |
| ÇÍÃì¿ÒÃÔ¹ | 1 | | 0.83 |
| ÂÒá¡éä¢éËÇÑ´ÍÂÙè㹡ÅØèÁÂÒ»ÃÐàÀ·ã´ | 1 | | 0.83 |
| âËÂè§àËÔ§ | 1 | | 0.83 |
| ÊٵëÙâ´ÍÕà¿´ÃÕ¹ ¤×ÍÍÐäà | 1 | | 0.83 |
| Êٵ÷ҧà¤ÁբͧÅÙ¡àËÁç¹ | 1 | | 0.83 |
| ¢¹Ò´ÂÒà«¿äµÃ | 1 | | 0.83 |
| ÂÒʵÃÕËÁÍÁÕ | 1 | | 0.83 |
| ÀÒ¾ÈÙ¹ÂìÇԷºÃÔ¡ÒÃÊӹѡ§Ò¹¤³Ð¡ÃÃÁ¡ÒÃÍÒËÒÃáÅÐÂÒ | 1 | | 0.83 |
| Áҵðҹ ¼Ñ¡Ê´ µÒÁÍÒËÒÃáÅÐÂÒ | 1 | | 0.83 |
| paper ¹èÒʹ㨠heart failure | 1 | | 0.83 |
| ºÃóҹءÃÁ âÀª¹ÒËÒúӺѴ âä¡Ðà¾ÒÐ | 1 | | 0.83 |
| swot ¢Í§¡ÒúԹä·Â | 1 | | 0.83 |
| ÂÒors | 1 | | 0.83 |
| ÊÃþ¤Ø³ÂÒ˧àËÔ§ | 1 | | 0.83 |
| type d personality | 1 | | 0.83 |
| ponstan Å´ä¢é | 1 | | 0.83 |
| disk cleanup automatically | 1 | | 0.83 |
| ¼ÙéãËèä¢éäÁèÂÍÁÅ´ | 1 | | 0.83 |
| ¡ÒâÖé¹·ÐàºÕ¹ Í | 1 | | 0.83 |
| ÂÒà«¿äµÃ | 1 | | 0.83 |
| ÈÙ¹ÂìÇԷºÃÔ¡ÒÃÍÂ. | 1 | | 0.83 |
| sulfamethazine ¤×Í | 1 | | 0.83 |
| ´Ê. ʸ. ¨Ñº µÔÇÒ¹¹·ì | 1 | | 0.83 |
| ÍÒËÒ÷Õèµè͵éÒ¹ÊÓËÃѺ¼Ùé»èÇ·Õè·Ò¹ÂÒÍÍ¿ÒÃÔ¹ | 1 | | 0.83 |
| overpopulation ºÃóҹءÃÁ | 1 | | 0.83 |
| ÍÒËÒÃÅ´¹éíÒ˹ѡ¢Í§¡ÃзÃǧÊÒ¸ÒóÊØ¢ | 1 | | 0.83 |
| ÍѹµÃÒ¨ҡÂÒàÊÃÔÁÊÁÃöÀÒ¾·Ò§à¾È | 1 | | 0.83 |
| Çѵ¶ØÍÍ¡Ä·¸ÔìµèͨԵáÅлÃÐÊÒ· ©ºÑº·Õè 3 ¾.È. 2535 | 1 | | 0.83 |
| ÃÒª×èÍÂÕèËéÍà¤Ã×èͧ»ÃاÃÊ | 1 | | 0.83 |
| ÃéÒ¹¨Ó˹èÒÂÂÒá¼¹âºÃÒ³ÊØÃÒÉ®Ãì¸Ò¹Õ | 1 | | 0.83 |
| ÂÒ midazolam | 1 | | 0.83 |
| ¡ÒÃÃѺ»ÃзҹÂÒá¡éËÇÑ´ | 1 | | 0.83 |
| ¤èÒÁÒµÃÒ°Ò¹¤èÒ t.l.v. (threshold limit value) | 1 | | 0.83 |
| ·èÒ¹¼ÙéËÔ§¾§Ò ¸ÃÃÁÈÑ¡´Ôì | 1 | | 0.83 |
| ÂÒªÒ+¡ÅØèÁ | 1 | | 0.83 |
| ÂÒá¡éä¢éËÇÑ´ãËè | 1 | | 0.83 |
| Êӹѡ§Ò¹¤³Ð¡ÃÃÁ¡ÒÃÍÒËÒÃáÅÐÂÒ | 1 | | 0.83 |
| ºÃÔÉÑ·âËÂè§àËÔ§ | 1 | | 0.83 |
| µÃÕàºâÅ·Óá·é§ä´é»èÒÇ | 1 | | 0.83 |
| ¡Ô¹ÂÒµÃÕ¹ÔÊÔ§àËà»ç¹ä§¡Ñ¹ºéÒ§ | 1 | | 0.83 |
| ÊÒÃ ä´ Íê Í¡ «Ô ¹ | 1 | | 0.83 |
| ÃÒ¤ÒÂÒ coxium | 1 | | 0.83 |
| «Ù¤ÃÒâÅÊ sucralose ¨Ó˹èÒ ¢Ò | 1 | | 0.83 |
| ÂÒá¡é ËÇÑ´ | 1 | | 0.83 |
| ÊÃþ¤Ø³ ÂÒ áÍÊä¾ÃÔ¹ | 1 | | 0.83 |
| ÊÔ¹¤éÒÊè§ÍÍ¡«ÍÊ»ÃاÃÊ | 1 | | 0.83 |
| mapping â·É¢Í§ÂÒàʾµÔ´ | 1 | | 0.83 |
| »Ùèà«Ô¹ ÍѹµÃÒ | 1 | | 0.83 |
| §Ò¹¾ÃÐÃÒª·Ò¹à¾ÅÔ§ÊÁà´ç¨ÂèÒ 8-10 | 1 | | 0.83 |
| ÂÒ˧àËÔ§ | 1 | | 0.83 |
| ¢ÒÂÂÒÊÒÁÑ»ÃШӺéҹἹ»Ñ¨ØºÑ¹áÅÐá¼¹âºÃÒ³µéͧ¢Í͹ØÒµËÃ×ÍäÁè | 1 | | 0.83 |
| ¡¯ÃÐàºÕº¢éͺѧ¤Ñº¢Í§âçàÃÕ¹àÁ¸ÒÃÑ¡Éì¡ÒúÃÔºÒÅ | 1 | | 0.83 |
| ¹íÒà¢éÒ | 1 | | 0.83 |
| ¹¾.ºØÊÒÁ | 1 | | 0.83 |
| clotrimazole Ê¡Ñ´¨Ò¡ | 1 | | 0.83 |
| ÂÒ miacalcic | 1 | | 0.83 |
| áËÅ觢éÁÙÅ www.fda.moph.go.th | 1 | | 0.83 |
| Ê¶ÔµÔ ãºÍ¹ØÒµ¢ÒÂÂÒ | 1 | | 0.83 |
| ÇÔ¸Õ·íÒà¹Â¶ÑèÇ | 1 | | 0.83 |
| ucl upper confidence limit | 1 | | 0.83 |
| ÍÂàµ×͹«Ñ¹¤ÒÃèÒËéÒÁ¢Ò | 1 | | 0.83 |
| â«áÅÁ ¤×Í | 1 | | 0.83 |
| alcohol dehydrogenase ÂÒ «×éÍ ¼ÊÁ ª×èÍ | 1 | | 0.83 |
| eprex 4000 | 1 | | 0.83 |
| midazolam ¤×Í | 1 | | 0.83 |
| ¨Ô§¨Ñ§´Á¡ÃÒÇ | 1 | | 0.83 |
| «Ùâ´ÍÕà¿´ÃÕ¹ pseudoephedrine | 1 | | 0.83 |
| ¡Ô¹ÂÒʵÃÕ¹ÔÊÔ§àË | 1 | | 0.83 |
| ÈÙ¹ÂìÊÒ¸ÒóÊØ¢ 17 ËÁÍÍÒÃÂÒ | 1 | | 0.83 |
| ¡ÒõԴµÑé§ apache tomcat\ | 1 | | 0.83 |
| ÂÒÃÑ¡ÉÒËÇÑ´ÁÕ¡Õè»ÃÐà¾È | 1 | | 0.83 |
| pseudoephedrine à»ç¹ÊÒõÑ駵éÃã¹ÂÒàʾµÔ´ä´éÍÂèÒ§äà | 1 | | 0.83 |
| ºÍáá«ì ºØµÒ ਹÊØ¢ÍØ´Á | 1 | | 0.83 |
| ·ÕèÍÂÙè ºÃÔÉÑ· à¨ÃÔâÍʶ | 1 | | 0.83 |
| ÊÕÂéÍÁºÃÔÅàÅÕ¹ºÅÙ | 1 | | 0.83 |
| thai pledge â¦É³Ò ¡ÒôÓà¹Ô¹¡Òà | 1 | | 0.83 |
| äÁèÃѺ»ÃзҹÍÒËÒÃàªéÒ ÊÁÒ¸ÔÊÑé¹ ¤ÁªÑ´ÅÖ¡ | 1 | | 0.83 |
| ÇÔµÒÁԹठÇÒÃì¿ÒÃÔ¹ | 1 | | 0.83 |
| cfcÍÂÙèã¹¼ÅÔµÀѳ±ìÍÐäà | 1 | | 0.83 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ (©ºÑº·Õè 164) ¾.È.2538 | 1 | | 0.83 |
| bacteriostatic ¤×Í | 1 | | 0.83 |
| «Ù¤ÃÒâÅÊ ÍѹµÃÒ | 1 | | 0.83 |
| ÇÔ¸Õ´ÙáŤ¹»èÇ·Õè¡Ô¹ÂÒÇÒ¿ÒÃÕ¹ | 1 | | 0.83 |
,
User's Guide
˹éÒÅçÍ¡ÍÔ¹| ʶԵÔÃÒ»Õ
| ʶԵÔÃÒÂà´×͹
| ʶԵÔÃÒÂÇѹ
| ʶԵÔÃÒªÑèÇâÁ§
| Eng
Pageview 
Unique IPs 
Sessions